Shenzhen IPOs raise a record US$33.6b in 2010 to trump Shanghai

According to the report, the growth follows the acceleration of IPO approvals in Shenzhen by the China Securities Regulatory Commission (CSRC), which has reportedly also become less involved in decisions concerning the pricing, timing and size of capital markets activity. Private equity groups are also increasingly viewing the stock exchange as being an attractive and potentially highly profitable means through which to exit from investments in China, especially having witnessed the huge profits made by Goldman Sachs on its US$5 million investment in pharmaceutical company Hepalink, which undertook a listing in April this year.